Assessment of breast cancer chemotherapy dose reduction in an integrated healthcare delivery system Journal Article
| Authors: | Kantor, E. D.; O’Connell, K.; Ergas, I. J.; Valice, E.; Roh, J. M.; Bhimani, J.; Heon, N.; Griggs, J. J.; Lee, J.; Bowles, E. J. A.; Rivera, D. R.; Kolevska, T.; Bandera, E. V.; Kushi, L. H. |
| Article Title: | Assessment of breast cancer chemotherapy dose reduction in an integrated healthcare delivery system |
| Abstract: | Purpose: Most cytotoxic drugs are dosed using body surface area (BSA), yet not all cancer patients receive the full BSA-determined dose. Prior work suggests that breast cancer patients who are obese are more likely to experience dose reduction than normal weight patients. However, the factors driving dose reduction remain unclear. Methods: In 452 women diagnosed with stage I-IIIA primary breast cancer at Kaiser Permanente Northern California, we evaluated the association between obesity and dose reduction, and further explored other factors in relation to dose reduction, including various sociodemographic characteristics, tumor characteristics, and comorbidities. Study participants were a part of the Pathways Study, diagnosed between 2006 and 2013 and treated with cyclophosphamide + doxorubicin, followed by paclitaxel (ACT). Dose reduction was assessed using first cycle dose proportion (FCDP) and average relative dose intensity (ARDI), a metric of dose intensity over the course of chemotherapy. Results: Overall, 8% of participants received a FCDP < 90% and 21.2% had an ARDI < 90%, with dose reduction increasing with body mass index. In adjusted logistic regression models, obese women had 4.1-fold higher odds of receiving an ARDI < 90% than normal weight women (95% CI: 1.9–8.9; p-trend = 0.0006). Increasing age was positively associated with an ADRI < 90%, as was the presence of comorbidity. Dose reduction was less common in later calendar years. Conclusion: Results offer insight on factors associated with chemotherapy dosing for a common breast cancer regimen. Larger studies are required to evaluate relevance to other regimens, and further work will be needed to determine whether dose reductions impact outcomes in obese women. © 2023, The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature. |
| Keywords: | cancer chemotherapy; aged; retrospective studies; major clinical study; doxorubicin; dose response; drug dose reduction; paclitaxel; chemotherapy; antineoplastic agent; demography; multiple cycle treatment; breast cancer; antineoplastic combined chemotherapy protocols; obesity; cyclophosphamide; breast neoplasms; retrospective study; body mass; breast tumor; comorbidity; health care delivery; socioeconomics; body surface; complication; delivery of health care, integrated; beta-alanine; integrated health care system; fumarates; humans; human; female; article; body surface area; drug tapering; beta alanine; fumaric acid; n(beta)-fumarylcarboxyamido-2,3-diaminopropionic acid |
| Journal Title: | Breast Cancer Research and Treatment |
| Volume: | 203 |
| Issue: | 3 |
| ISSN: | 0167-6806 |
| Publisher: | Springer |
| Date Published: | 2024-02-01 |
| Start Page: | 565 |
| End Page: | 574 |
| Language: | English |
| DOI: | 10.1007/s10549-023-07126-4 |
| PUBMED: | 37923962 |
| PROVIDER: | scopus |
| PMCID: | PMC10885738 |
| DOI/URL: | |
| Notes: | Article -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work